Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 27

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 27
---
, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca .

Cautionary statements regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement:

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things:

- the risk of failure or delay in delivery of pipeline or launch of new medicines;

- the risk of failure to meet regulatory or ethical requirements for medicine development or approval;

- the risk of failures or delays in the quality or execution of the Group's commercial strategies;

- the risk of pricing, affordability, access and competitive pressures;

- the risk of failure to maintain supply of compliant, quality medicines;

- the risk of illegal trade in the Group's medicines;

- the impact of reliance on third-party goods and services;

- the risk of failure in information technology or cybersecurity;

- the risk of failure of critical processes;

- the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives;

- the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce;

- the risk of failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment;

- the risk of the safety and efficacy of marketed medicines being questioned;

- the risk of adverse outcome of litigation and/or governmental investigations;

- intellectual property